Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include very common findings: Seizure, Global developmental delay, Coarse facial features, and Failure to thrive in infancy; and common findings: Microcephaly, Brain shrinkage (cerebral atrophy), Profound intellectual disability, and Low muscle tone (hypotonia) and others. 45 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 20 | Brain shrinkage (cerebral atrophy), Seizure, Profound intellectual disability |
Kidneys and urinary system | 5 | Protein in the urine (proteinuria), Decreased glomerular filtration rate, Chronic kidney disease |
Muscles | 4 | Brain shrinkage (cerebral atrophy), Low muscle tone (hypotonia), Cerebral cortical atrophy |
Head and neck | 3 | Microcephaly, Coarse facial features, Progressive microcephaly |
Eyes | 3 | Strabismus, Visual impairment, Nystagmus |
Growth and development | 1 | Failure to thrive in infancy |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Digestive system | 1 | Difficulty swallowing (dysphagia) |
PUS3 function has not been fully characterized.
Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome is associated with mutations in the PUS3 gene on chromosome 11.
Genetic testing for PUS3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome has been reported in the published literature.
Phenotype severity distribution: 4 very common features, 14 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome.
9 publications have been identified in PubMed for severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome. Research spans Review / Meta-Analysis (25%), Case Report / Case Series (25%), and Diagnostic / Biomarker (13%).
Filipic M (2026). [PMID: 41623317](https://pubmed.ncbi.nlm.nih.gov/41623317/). *Mol Genet Metab Rep*. [Review / Meta-Analysis]
Harripaul R (2026). [PMID: 41865132](https://pubmed.ncbi.nlm.nih.gov/41865132/). *Sci Rep*. [Basic Science / Preclinical]
Kakar N (2025). [PMID: 39708122](https://pubmed.ncbi.nlm.nih.gov/39708122/). *Hum Genet*. [Case Report / Case Series]
Sandal S (2024). [PMID: 37804371](https://pubmed.ncbi.nlm.nih.gov/37804371/). *Indian J Pediatr*. [Diagnostic / Biomarker]
Gebert J (2024). [PMID: 38286424](https://pubmed.ncbi.nlm.nih.gov/38286424/). *Neuropediatrics*. [Case Report / Case Series]
Ahmed AN (2024). [PMID: 39415096](https://pubmed.ncbi.nlm.nih.gov/39415096/). *BMC Neurol*. [Epidemiology / Natural History]
Scaravilli A (2024). [PMID: 38880819](https://pubmed.ncbi.nlm.nih.gov/38880819/). *J Neurol*. [Clinical Trial Publication]
Wang J (2024). [PMID: 39344621](https://pubmed.ncbi.nlm.nih.gov/39344621/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Review / Meta-Analysis]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 7:14 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center